Guizhou Sanli Pharmaceutical Co.,Ltd

XSSC:603439 Stock Report

Market Cap: CN¥5.5b

Guizhou Sanli PharmaceuticalLtd Past Earnings Performance

Past criteria checks 4/6

Guizhou Sanli PharmaceuticalLtd has been growing earnings at an average annual rate of 26%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 23.6% per year. Guizhou Sanli PharmaceuticalLtd's return on equity is 18.1%, and it has net margins of 15.6%.

Key information

26.0%

Earnings growth rate

24.2%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate23.6%
Return on equity18.1%
Net Margin15.6%
Next Earnings Update26 Apr 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Guizhou Sanli PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

XSSC:603439 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 242,1133291,08642
30 Jun 241,9253091,00938
31 Mar 241,70829490734
31 Dec 231,63529388331
30 Sep 231,46125675625
30 Jun 231,40223872826
31 Mar 231,39223271922
31 Dec 221,20120162818
30 Sep 221,03514455716
30 Jun 2299214752810
31 Mar 229681535139
31 Dec 219391524948
30 Sep 218811574515
30 Jun 217251173735
31 Mar 21612923136
31 Dec 20630943056
30 Sep 20676883354
30 Jun 208181243882
31 Mar 208881374174
31 Dec 198841334214
30 Jun 197711083789
31 Mar 197541043687
31 Dec 187221103587
30 Jun 187001203470
31 Mar 186651063430
31 Dec 17638883243
30 Sep 17597773080
30 Jun 17556662920
31 Mar 17501682540
31 Dec 16515752560
30 Sep 16464692250
30 Jun 16414631930
31 Mar 16386581800
31 Dec 15359531660
30 Sep 15325461500
30 Jun 15291401360
31 Mar 15279341330
31 Dec 14267291290
31 Dec 1315919780

Quality Earnings: 603439 has high quality earnings.

Growing Profit Margin: 603439's current net profit margins (15.6%) are lower than last year (17.5%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 603439's earnings have grown significantly by 26% per year over the past 5 years.

Accelerating Growth: 603439's earnings growth over the past year (28.7%) exceeds its 5-year average (26% per year).

Earnings vs Industry: 603439 earnings growth over the past year (28.7%) exceeded the Pharmaceuticals industry -2.5%.

Return on Equity

High ROE: 603439's Return on Equity (18.1%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/28 16:31
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Guizhou Sanli Pharmaceutical Co.,Ltd is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yin YePing An Securities Co. Ltd.
Mengmeng HanPing An Securities Co. Ltd.
Song YangTianfeng Securities Brokerage Co., Ltd